Sabol K E, Seiden L S
University of Mississippi, Department of Psychology, 301 Peabody Bldg., University, MS 38677, USA.
Brain Res. 1998 Sep 21;806(1):69-78. doi: 10.1016/s0006-8993(98)00720-3.
Amphetamine releases dopamine through a transporter-mediated mechanism. The purpose of this report was to further our understanding of the intracellular pool from which amphetamine releases dopamine: the cytoplasmic pool, the vesicular pool, or both. Rats were treated with D-amphetamine (AMPH) (1.0 or 10.0 mg/kg) or an amphetamine analog, methylenedioxymethamphetamine (MDMA) (2.0, 5.0, or 10.0 mg/kg). Pre-treatment with 10.0 mg/kg reserpine (18 h prior to AMPH or MDMA) attenuated dopamine release for high and low AMPH doses; however the low-dose effect showed borderline significance. Pre-treatment with 10.0 mg/kg reserpine attenuated dopamine and serotonin release induced by MDMA. The dopamine effect was seen at all three MDMA doses; the effect on serotonin was only measured at the 10.0 mg/kg dose. Reserpine pre-treatment caused reductions in core body temperature; heating the rats to normal body temperature for 3 h prior to AMPH or MDMA, and during the 4 h post-treatment period partially reversed the reserpine-induced attenuation of dopamine release. However, the intermediate level of dopamine release for the reserpinized-heated animals was not significantly different from either the reserpine group (not heated) or the AMPH or MDMA alone groups. In a separate group of rats, the effects of reserpine and reserpine+heat on dopamine synthesis were measured. DOPA accumulation after treatment with the aromatic acid decarboxylase inhibitor NSD-1015 (100 mg/kg, 30 min before sacrifice), was greater in rats treated with reserpine compared to controls; heating the reserpinized rats did not significantly alter the amount of DOPA accumulation; however there was a trend towards further increase. These results suggest that D-amphetamine releases dopamine that is stored in both vesicles and the cytoplasm. Cooling may contribute to the attenuation of AMPH or MDMA-induced dopamine release observed after reserpine; however, AMPH or MDMA dependence upon vesicular stores most likely explains the diminished release after reserpine. The attenuation of AMPH or MDMA-induced transmitter release by reserpine is thought to be counteracted by a reserpine-induced replenishment of stores. Therefore, all doses of D-amphetamine may use vesicular stores; the degree to which new synthesis counteracts the vesicular depletion may be the variable which differentiates low from high doses of D-amphetamine.
安非他命通过一种转运体介导的机制释放多巴胺。本报告的目的是进一步了解安非他命从中释放多巴胺的细胞内池:细胞质池、囊泡池或两者皆有。用D-安非他命(AMPH)(1.0或10.0毫克/千克)或一种安非他命类似物,3,4-亚甲基二氧基甲基苯丙胺(摇头丸,MDMA)(2.0、5.0或10.0毫克/千克)处理大鼠。用10.0毫克/千克利血平预处理(在给予AMPH或MDMA前18小时)可减弱高剂量和低剂量AMPH引起的多巴胺释放;然而,低剂量效应显示出临界显著性。用10.0毫克/千克利血平预处理可减弱MDMA诱导的多巴胺和5-羟色胺释放。在MDMA的所有三个剂量下都观察到了多巴胺效应;对5-羟色胺的效应仅在10.0毫克/千克剂量下进行了测量。利血平预处理导致核心体温降低;在给予AMPH或MDMA前将大鼠加热至正常体温3小时,并在处理后4小时期间部分逆转了利血平诱导的多巴胺释放减弱。然而,利血平化加热动物的多巴胺释放中间水平与利血平组(未加热)或单独给予AMPH或MDMA组相比无显著差异。在另一组大鼠中,测量了利血平和利血平+加热对多巴胺合成的影响。在用芳香酸脱羧酶抑制剂NSD-1015(100毫克/千克,处死前30分钟)处理后,与对照组相比,用利血平处理的大鼠中多巴积累更多;加热利血平化大鼠并未显著改变多巴积累量;然而有进一步增加的趋势。这些结果表明,D-安非他命释放储存在囊泡和细胞质中的多巴胺。降温可能导致利血平后观察到的AMPH或MDMA诱导的多巴胺释放减弱;然而,AMPH或MDMA对囊泡储存的依赖性最有可能解释利血平后释放减少的原因。利血平对AMPH或MDMA诱导的递质释放的减弱作用被认为可被利血平诱导的储存补充所抵消。因此,所有剂量的D-安非他命可能都利用囊泡储存;新合成抵消囊泡耗竭的程度可能是区分低剂量和高剂量D-安非他命的变量。